Group | Total number of lesions | Lesions measured | Average SUVmax at baseline | Average SUVmax at follow-up | Average increase in SUVmax (%) |
---|---|---|---|---|---|
Group A | |||||
1 | 13 | 2 | 7.1 | 12.1 | 71 |
2 | 6 | 5 | 8.8 | 12.8 | 75 |
3 | 1 | 1 | 16.7 | 12.3 | −26 |
4 | 4 | 3 | 3.8 | 4.4 | 22 |
5 | 1 | 1 | 5.3 | 12.8 | 142 |
6 | 14 | 6 | 8.7 | 7.0 | −17 |
7 | 3 | 3 | 6.2 | 7.6 | 23 |
8 | 4 | 4 | 6.3 | 5.3 | −16 |
9 | 18 | 6 | 9.9 | 9.9 | 1 |
10 | 4 | 3 | 7.2 | 6.2 | 0 |
Mean increase in SUVmax | 38% | ||||
Group B | |||||
11 | 3 | 2 | 5.9 | 6.4 | 9 |
12 | 3 | 3 | 5.6 | 4.4 | −23 |
13 | 1 | 1 | 5.4 | 6.0 | 11 |
14 | 4 | 2 | 11.5 | 15.8 | 43 |
15 | 6 | 6 | 7.6 | 8.3 | 13 |
16 | 1 | 1 | 7.8 | 2.3 | −57 |
17 | 2 | 2 | 5.2 | 13.7 | 179 |
18 | 1 | 1 | 2.2 | 1.6 | −27 |
19 | 1 | 1 | 1.7 | 1.6 | −6 |
20 | 1 | 1 | 5.4 | 4.5 | −17 |
21 | 2 | 2 | 5.6 | 5.1 | −4 |
Mean increase in SUVmax | −11% |
Patients 3, 9, and 14 were excluded from further analyses because initial SUVmax for most metastatic lesions was >10. Patient 17 was excluded because second liver metastasis developed just adjacent to first metastasis, making measurement of separate SUVs impossible.